摘要
目的比较表阿霉素联合多西紫杉醇新辅助化疗方案(ET方案)对三阴乳腺癌(TNBC)和非三阴乳腺癌(non-TNBC)的临床疗效及预后差别。方法回顾性分析接受ET新辅助化疗方案治疗的198例乳腺癌患者的临床资料,依据免疫组化结果将乳腺癌分为TNBC及non-TNBC两组,对两类乳腺患者接受ET新辅助化疗方案后的病理疗效及预后的差别进行分析比较。结果 198例乳腺癌患者中,TNBC43例,non-TNBC155例。所有患者的临床总有效率(cOR)为76.8%,其中完全缓解率24.7%,部分缓解率48.5%;TNBC患者的临床有效率84.2%,病理完全缓解率(pCR)27.9%;non-TNBC患者临床有效率70.4%,病理完全缓解率12.9%。TNBC患者与非TNBC患者5年无病生存率(DFS)分别为52.9%和70.9%(P<0.05);TNBC患者与非TNBC患者5年总体生存率分别为59.1%和80.5%(P<0.05)。结论表阿霉素联合多西紫杉醇新辅助化疗方案治疗三阴乳腺癌患者能够获得较好的临床效果。
Objective To investigate the effect of the neoadjuvant epirubicin plus paclitaxel chemotherapy and survival in patients with triple-negative breast cancer （TNBC） and non-TNBC. Methods One hundred and ninety-eight patients treated with neoadjuvant chemotherapy were included in this retrospective study. All the patients were classified as TNBC and non-TNBC according the immuuohistochemical examination. TNBC was defined as the lack of estrogen receptor （ER）, progesterone receptor （PR） and HER2 status expression. The treatment effects and survival rates were compared between two groups. Results Of 198 cases, 43 were confirmed TNBC, 155 were nonTNBC. In all patients, the clinical overall response rate was 76.8%, the clinical complete remission was 24.7%, and the partial response rate was 48.5%. The clinical response rate, pathological complete remission rate, 5-year disease free survival （DFS）, and 5-year overall survival （OS） in TNBC group showed the differences when compared with non-TNBC group （84.2% vs 70.4%, 27.9% vs 12.9%, 52.9% vs 70.9%, 59.1% vs 80.5%, respectively, all P〈0.05）. Conclusion The neoadjuvant epirubicin plus paclitaxel chemotherapy showed a better effect in patients with TNBC as compared to those with non-TNBC.
出处
《岭南现代临床外科》
2012年第4期350-353,共4页
Lingnan Modern Clinics in Surgery
关键词
乳腺肿瘤
三阴乳腺癌
新辅助化疗
预后
Breast neoplasms
Triple-negative breast cancer
Neoadjuvant chemotherapy
Prognosis
